Extrapolated to cancer patients this could mean that GABARAPL1 blocking antibodies could inhibit angiogenesis or neovascularisation and thereby inhibit tumour growth and increase susceptibility to therapeutic interventions. The gene discussed is GABARAPL1; the disease is cancer.